Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.

Autor: De La Garza R 2nd; Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, United States. Electronic address: rg12@bcm.edu., Bubar MJ; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States., Carbone CL; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States., Moeller FG; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States; Institute for Drug and Alcohol Studies, Addiction Medicine, Virginia Commonwealth University, Richmond, VA, United States., Newton TF; Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, United States., Anastasio NC; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, United States., Harper TA; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, United States., Ware DL; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States; Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States., Fuller MA; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States; Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX, United States., Holstein GJ; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States; Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX, United States., Jayroe JB; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States; Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States., Bandak SI; Biotie Therapies, Inc. (formerly Synosia Therapeutics), South San Francisco, CA, United States., Reiman KZ; Biotie Therapies, Inc. (formerly Synosia Therapeutics), South San Francisco, CA, United States., Neale AC; Biotie Therapies, Inc. (formerly Synosia Therapeutics), South San Francisco, CA, United States., Pickford LB; Biotie Therapies, Inc. (formerly Synosia Therapeutics), South San Francisco, CA, United States., Cunningham KA; Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, United States; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, United States.

Publikováno v: Progress in neuro-psychopharmacology & biological psychiatry [Prog Neuropsychopharmacol Biol Psychiatry] 2015 Jun 03; Vol. 59, pp. 40-48. Date of Electronic Publication: 2015 Jan 17.

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

Autor: Black KJ; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA. kevin@wustl.edu, Koller JM, Campbell MC, Gusnard DA, Bandak SI

Publikováno v: The Journal of neuroscience : the official journal of the Society for Neuroscience [J Neurosci] 2010 Dec 01; Vol. 30 (48), pp. 16284-92.